Low-Powered View, High-Powered Mind: A Case Report of Morpheaform Basal Cell Carcinoma Mistaken for Metastatic Breast Carcinoma.
| Autor: | Imlay RK; Surgery, West Virginia University School of Medicine, Charleston, USA., Perez Torrico C; Surgery, West Virginia University School of Medicine, Charleston, USA., Sulaimann A; Pathology, West Virginia University, Morgantown, USA., Grimes ZM; Pathology, Charleston Area Medical Center, Charleston, USA., Monnett S; General Surgery, Charleston Area Medical Center/West Virginia University, Charleston, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Feb 14; Vol. 16 (2), pp. e54174. Date of Electronic Publication: 2024 Feb 14 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.54174 |
| Abstrakt: | Basal cell carcinoma (BCC) is one of the most common skin malignancies worldwide. Morpheaform basal cell carcinoma (MBCC) is a rare aggressive subtype of BCC that presents with unique histologic features. Both are treated surgically and have an excellent survival rate. Metastatic breast carcinoma, on the other hand, has a poor survival rate along with a more burdensome therapeutic route including chemotherapy. Due to an overlap in common immunohistochemistry stains, there is a possibility of confusing the diagnosis of BCC with metastatic breast carcinoma resulting in potential patient harm. Therefore, a timely and accurate diagnosis distinguishing these malignancies is essential. We report a near-miss event in which a 77-year-old female with MBCC was mistakenly diagnosed with metastatic breast carcinoma. We discuss the details of these stains, characteristic features of MBCC, and treatment options and emphasize the importance of combining laboratory medicine with clinical expertise to improve patient outcomes. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Imlay et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|